在整合酶区域携带E157Q突变病毒的患者中，对含多替拉韦的治疗方案无病毒学应答。 - Suppr

Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region.

作者信息

Danion F, Belissa E, Peytavin G, Thierry E, Lanternier F, Scemla A, Lortholary O, Delelis O, Avettand-Fenoel V, Duvivier C

机构信息

APHP-Hôpital Necker-Enfants malades, Service de Maladies Infectieuses et Tropicales, Centre d'Infectiologie Necker-Pasteur, Paris, France Université Paris Descartes, Sorbonne Paris Cité, Paris, France IHU Imagine, Paris, France.

AP-HP, Groupe Hospitalier Xavier Bichat-Claude Bernard, UF 301 Laboratoire de Pharmaco-Toxicologie, F-75018 Paris, France.

出版信息

J Antimicrob Chemother. 2015;70(6):1921-3. doi: 10.1093/jac/dkv012. Epub 2015 Feb 10.

DOI:10.1093/jac/dkv012

PMID:25670643

Abstract

摘要

相似文献

Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region.在整合酶区域携带E157Q突变病毒的患者中，对含多替拉韦的治疗方案无病毒学应答。

J Antimicrob Chemother. 2015;70(6):1921-3. doi: 10.1093/jac/dkv012. Epub 2015 Feb 10.

Dolutegravir-based regimen maintains virological success in a patient with archived mutations to integrase inhibitors.基于多替拉韦的治疗方案在一名对整合酶抑制剂存在既往突变的患者中维持了病毒学疗效。

AIDS. 2017 Aug 24;31(13):1900-1901. doi: 10.1097/QAD.0000000000001581.

Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors.HIV整合酶中针对多替拉韦的耐药性突变会削弱对逆转录酶抑制剂耐药性的出现。

AIDS. 2014 Mar 27;28(6):813-9. doi: 10.1097/QAD.0000000000000199.

Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity.HIV-1整合酶中的多态性替代E157Q增加了R263K介导的多替拉韦耐药性并降低了DNA结合活性。

J Antimicrob Chemother. 2016 Aug;71(8):2083-8. doi: 10.1093/jac/dkw109. Epub 2016 Apr 15.

The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro.HIV-1 整合酶 E157Q 多态性本身不会改变体外对拉替拉韦和多替拉韦的敏感性。

AIDS. 2017 Oct 23;31(16):2307-2309. doi: 10.1097/QAD.0000000000001616.

Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen.分析 HIV-1 E157Q 整合酶多态性表型及其对接受整合酶抑制剂方案治疗的患者病毒学结局的影响。

J Antimicrob Chemother. 2018 Apr 1;73(4):1039-1044. doi: 10.1093/jac/dkx511.

Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.新型通路致携带 N155H 及多种耐药突变患者对多替拉韦耐药的演变。

J Antimicrob Chemother. 2015 Feb;70(2):405-11. doi: 10.1093/jac/dku387. Epub 2014 Oct 3.

Dolutegravir: successful experience in a challenging patient.多替拉韦：在一位具有挑战性的患者身上的成功经验。

AIDS. 2015 Jun 19;29(10):1269-71. doi: 10.1097/QAD.0000000000000696.

Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients.多替拉韦功能单药疗法对整合酶链转移抑制剂耐药患者的HIV-1病毒学应答的影响。

Antivir Ther. 2016;21(6):481-488. doi: 10.3851/IMP3033. Epub 2016 Feb 11.

The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors.S230R 整合酶取代与多替拉韦单药治疗期间病毒载量反弹相关，导致对整合酶链转移抑制剂的低水平耐药。

J Infect Dis. 2018 Jul 24;218(5):698-706. doi: 10.1093/infdis/jiy175.

引用本文的文献

High prevalence of reverse transcriptase inhibitors associated resistance mutations among people living with HIV on dolutegravir-based antiretroviral therapy in Francistown, Botswana.在博茨瓦纳弗朗西斯敦接受基于多替拉韦的抗逆转录病毒治疗的艾滋病毒感染者中，逆转录酶抑制剂相关耐药突变的高流行率。

J Antimicrob Chemother. 2025 Mar 3;80(3):767-776. doi: 10.1093/jac/dkae472.

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.在使用卡替拉韦、比克替拉韦、多替拉韦和艾维雷韦的患者来源的临床分离株中出现的选择性耐药谱。

Retrovirology. 2018 Aug 17;15(1):56. doi: 10.1186/s12977-018-0440-3.

Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and available of integrase inhibitors in Cape Town, South Africa.南非国家艾滋病毒治疗计划前的 HIV-1 整合酶序列分析和南非开普敦整合酶抑制剂的可及性。

Sci Rep. 2018 Mar 16;8(1):4709. doi: 10.1038/s41598-018-22914-5.

Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.无HIV-1耐药突变支持在乌干达使用多替拉韦。

AIDS Res Hum Retroviruses. 2018 May;34(5):404-414. doi: 10.1089/AID.2017.0205. Epub 2018 Feb 26.

Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.HIV 整合酶抑制剂耐药性：关于 R263K 和 E157Q 突变。

Viruses. 2018 Jan 18;10(1):41. doi: 10.3390/v10010041.

Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.基于规则的专家系统用于HIV-1基因型耐药性检测解读的协同更新

PLoS One. 2017 Jul 28;12(7):e0181357. doi: 10.1371/journal.pone.0181357. eCollection 2017.

HIV drug resistance against strand transfer integrase inhibitors.HIV 对链转移整合酶抑制剂的耐药性。

Retrovirology. 2017 Jun 5;14(1):36. doi: 10.1186/s12977-017-0360-7.

Analysis of HIV Integrase Resistance in Black Men Who Have Sex with Men in the United States.美国男男性行为黑人中HIV整合酶耐药性分析

AIDS Res Hum Retroviruses. 2017 Jul;33(7):745-748. doi: 10.1089/aid.2017.0005. Epub 2017 Apr 6.

J Antimicrob Chemother. 2016 Aug;71(8):2083-8. doi: 10.1093/jac/dkw109. Epub 2016 Apr 15.

Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.含有N155H和R263K耐药性替代的多替拉韦选择的HIV-1在药物压力下不会获得导致更高水平耐药性和复制能力增加的额外补偿性突变。

J Virol. 2015 Oct;89(20):10482-8. doi: 10.1128/JVI.01725-15. Epub 2015 Aug 5.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献